A recent study [97] provides evidence that KDM5D plays an important role in determining docetaxel sensitivity, which is used in treating prostate cancer, by interacting with androgen receptor signalling and that its expression level is associated with clinical outcomes. This evidence concerns the gene KDM5D and prostate carcinoma.